MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on October 1, 2004; DOI: 10.1124/mol.104.005579


0026-895X/05/6701-220-230$20.00
Mol Pharmacol 67:220-230, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.005579v1
67/1/220    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liang, S.-H.
Right arrow Articles by Omiecinski, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liang, S.-H.
Right arrow Articles by Omiecinski, C. J.

Alternative Promoters Determine Tissue-Specific Expression Profiles of the Human Microsomal Epoxide Hydrolase Gene (EPHX1)

Shun-Hsin Liang, Christopher Hassett, and Curtis J. Omiecinski

Center for Molecular Toxicology and Carcinogenesis, the Pennsylvania State University, University Park, Pennsylvania

Microsomal epoxide hydrolase (EPHX1) catalyzes hydration reactions that determine the cellular disposition of reactive epoxide derivatives. Whereas the previously defined EPHX1 exon 1 sequence (E1) is derived from a promoter proximal to exon 2 of the EPHX1 coding region, in this investigation, we identified an alternative EPHX1 exon 1 sequence, E1-b, originating from a gene promoter localized ~18.5 kb upstream of exon 2. Northern hybridizations demonstrated that the E1-b variant is widely expressed and that the E1-b promoter functions as the primary driver of EPHX1 expression in human tissues. In contrast, the E1 promoter directs expression only in the liver. To examine the basis for liver-specific usage of the E1 promoter, we identified several potential cis-regulatory elements that included GATA (-110/-105) and hepatocyte nuclear factor 3 (HNF3) (-96/-88) motifs. GATA-4 was the principal GATA family member interacting with its respective motif, whereas both HNF3{alpha} and HNF3{beta} were capable of interacting with the HNF3 element. GATA-4 and HNF3{alpha}/HNF3{beta} DNA binding complexes were enriched in hepatic cells. Site-directed mutagenesis and transactivation analyses of the E1 promoter revealed that GATA-4 is probably a principal factor that regulates liver-specific expression of the E1 variant, with HNF3{alpha} and HNF3{beta} acting to negatively regulate GATA-4 function in hepatic cells.


Received July 29, 2004; accepted September 29, 2004

Address correspondence to: Dr. Curtis Omiecinski, Center of Molecular Toxicology, 115 Henning, Pennsylvania State University, University Park, PA 16802. E-mail: cjo10{at}psu.edu




This article has been cited by other articles:


Home page
Toxicol SciHome page
S. Z. Abdel-Rahman, M. M. Ammenheuser, C. J. Omiecinski, J. K. Wickliffe, J. I. Rosenblatt, and J. B. Ward Jr.
Variability in Human Sensitivity to 1,3-Butadiene: Influence of Polymorphisms in the 5'-Flanking Region of the Microsomal Epoxide Hydrolase Gene (EPHX1)
Toxicol. Sci., May 1, 2005; 85(1): 624 - 631.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics